Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16
Compose a Response to This Article
Other responses
No responses have been published for this article.
